Back to the future: how biology and technology could change the role of PTFE grafts in vascular access management.
Back to the future: how biology and technology could change the role of PTFE grafts in vascular access management.
复制标题
回到未来：生物学和技术如何改变 PTFE 移植物在血管通路管理中的作用。
DOI：
10.1111/j.1525-139x.2012.01091.x
复制
发表时间：
2012
影响因子：
1.6
通讯作者：
Munda,Rino
中科院分区：
文献类型：
--
作者：
Roy-Chaudhury,Prabir;El-Khatib,Mahmoud;Campos-Naciff,Begona;Wadehra,Davinder;Ramani,Karthik;Leesar,Massoud;Mistry,Meenakshi;Wang,Yang;Chan,Jenq-Shyong;Lee,Timmy;Munda,Rino
尽管动静脉瘘(AVF)是透析血管通路的首选模式，但AVF成熟失败仍然是一个巨大的临床问题，经常导致隧道透析管的使用时间延长。相比之下，聚四氟乙烯(PTFE)移植物不会遭受早期失败，但在以后的狭窄和血栓形成方面存在重大问题。本文将首先总结PTFE移植物功能障碍的病理和发病机制，然后以此为基础描述一些新的治疗方法，这些治疗方法可能有可能减少PTFE移植物功能障碍。最后，我们将强调，这种疗法的引入可能是朝着个性化整体血管通路护理迈出的重要的第一步。
Although the arteriovenous fistula (AVF) is the preferred mode of dialysis vascular access, AVF maturation failure remains a huge clinical problem, often resulting in a prolonged duration of use of tunneled dialysis catheters. In contrast, polytetrafluoroethylene (PTFE) grafts do not suffer from early failure, but have significant problems with later stenosis and thrombosis. This review will initially summarize the pathology and pathogenesis of PTFE graft dysfunction and will then use this as a basis for describing some novel therapies, which may have the potential to reduce PTFE graft dysfunction. Finally, we will emphasize that the introduction of such therapies could be an important first step toward individualizing overall vascular access care.